NA
RNAM

NewEdge Advisors’s Avidity Biosciences RNAM Stock Holding History

NewEdge Advisors’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,615
Closed -$621K – 4350
2025
Q4 		$621K Sell
8,615
-20,596
-71% -$1.33M ﹤0.01% 1811
2025
Q3 		$1.27M Buy
29,211
+4,069
+16% +$164K 0.01% 1261
2025
Q2 		$714K Buy
25,142
+1,305
+5% +$38.9K ﹤0.01% 1479
2025
Q1 		$704K Buy
23,837
+4,410
+23% +$137K ﹤0.01% 1389
2024
Q4 		$565K Buy
19,427
+1,412
+8% +$59K ﹤0.01% 1469
2024
Q3 		$827K Buy
18,015
+7,048
+64% +$306K 0.01% 1188
2024
Q2 		$448K Buy
+10,967
New +$315K ﹤0.01% 1476
2023
Q1 		– Sell
-49
Closed -$1.09K – 3998
2022
Q4 		$1.09K Buy
+49
New +$731 ﹤0.01% 3014

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

NewEdge Advisors's RNAM Position: Q1 2026 in Review

NewEdge Advisors sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 8,615 shares — an estimated $621K sold.

NewEdge Advisors first reported a position in RNAM in Q4 2022 and held it in 8 quarters. The position peaked at $1.27M in Q3 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • NewEdge Advisors reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • NewEdge Advisors sold 8,615 Avidity Biosciences shares in Q1 2026, an estimated $621K.
  • NewEdge Advisors first reported a position in Avidity Biosciences in Q4 2022 and held it in 8 quarters.
  • NewEdge Advisors's Avidity Biosciences position peaked at $1.27M in Q3 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.